OptiNose to begin Phase III trials with intranasal technology - Pharmaceutical Business Review
OptiNose to begin Phase III trials with intranasal technologyPharmaceutical Business ReviewOptiNose, a drug delivery company, has filed an investigational new drug (IND) with the FDA to use sumatriptan delivered with its novel drug delivery technology, in December 2011.
NuPathe to Present at Upcoming Investor Conferences - MarketWatch (press release)
NuPathe to Present at Upcoming Investor ConferencesMarketWatch (press release)NuPathe's lead product candidate, NP101, is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine.
NuPathe to Present at Upcoming Investor Conferences - Marketwire (press release)
NuPathe to Present at Upcoming Investor ConferencesMarketwire (press release)NuPathe's lead product candidate, NP101, is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine.
OptiNose testing nose-to-brain delivery tech with migraine drug - FierceDrugDelivery
OptiNose testing nose-to-brain delivery tech with migraine drugFierceDrugDeliveryOptiNose is launching a Phase III trial to test the migraine drug sumatriptan with its intranasal nose-to-brain drug delivery technology.
NuPathe Announces Allowance of Additional U.S. Patent Application for Its ... - MarketWatch (press release)